PORTON DOWN, England, October 22 /PRNewswire/ --
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that it has signed a third licence agreement with Applied Biosystems.
The licence provides Enigma with access to claims of US Patent No. 5,928,907 that describe methods for monitoring nucleic acid amplification in real-time. This is the first such licence Applied Biosystems has granted to the method claims of the '907 patent.
This complements Enigma's existing licence under certain patents owned by Applied Biosystems for real-time PCR thermal cyclers.
Financial terms were not disclosed.
Contacts UK Contact: Enigma Diagnostics Deborah Cordingley email@example.com +44-1980-590131 US Contact: Richard Lewis Communications, Inc. +1-212-827-0020 Gregory Tiberend - Media firstname.lastname@example.org Megan Dubrowski - Media email@example.com Cecelia Heer - Investors firstname.lastname@example.org
Notes to editors:
About Enigma Diagnostics Limited
Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.
Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.
The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.
Enigma has an exclusive licence from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's RD activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.
For more information visit www.enigmadiagnostics.com
Web site: http://www.enigmadiagnostics.com
Deborah Cordingley, Enigma Diagnostics, +44-1980-590131, email@example.com, or media, Gregory Tiberend, +1-212-827-0020, firstname.lastname@example.org or Megan Dubrowski, +1-212-827-0020, email@example.com, both of Richard Lewis Communications, Inc.; or investors, Cecelia Heer, +1-212-827-0020, firstname.lastname@example.org